Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones. The first CVR payment of $0.50 per share (or $87.5 million) would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR payment of $0.50 per share ($87.5 million) would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing of the acquisition.

Looking ahead in 2009

ViroPharma is providing guidance for the year 2009 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following

  • Net product sales are expected to be $250 to $270 million. This guidance assumes no generic versions of Vancocin are approved in 2009 and excludes any revenue guidance for Cinryze.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $130 to $145 million, which includes approximately $25 million of expenses and previous commitments related to maribavir. SFAS 123R expenses are expected to be between $11 and $13 million.

Conference Call and Webca
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
(Date:3/3/2015)... , March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: ... proprietary technologies and products for advanced microarray diagnostics, ... CA, CFE  to its Management team. In his ... in its transition from a development stage to ... to advance the Company,s capital market strategy and ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... Md. , March 3, 2015  RegeneRx Biopharmaceuticals, ... editorial in the scientific journal, Expert Opinion on ... his colleague, Dr. Zhenggang Zhang , at the ... reported that Thymosin beta 4 (TB4) has the ... remodeling 24 hours or more post-injury, leading to neurological ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... Feature Public and Private Life Science Companies from ... ... for the,Southern California life science community, is proud to announce that ... Diego,Marriott Del Mar from Oct. 31-Nov. 2, 2007. Featuring almost ...
... Tissue Ligating ... ... surgical device company, has been named a 2007 Innovator of the,Year ... for its newest Tissue Ligating Shears, the TLS3,which uses the Company,s ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2BIOCOM Announces Second Annual Investor Conference 2Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 2
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015  Businesses have ... Data protection company Tharon Rankins Enterprises has announced ... provides an ultra-safe way for businesses to protect ... financial transactions. Beconux is a ... Rankins Enterprises. Functioning similarly to an ATM machine, ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... PASADENA, Calif.A California Institute of Technology (Caltech)-led ... first proof that a targeted nanoparticleused as an ... bloodstreamcan traffic into tumors, deliver double-stranded small interfering ... gene using a mechanism known as RNA interference ...
... A potential new energy source so controversial that people once ... by the mainstream scientific community. That,s the conclusion of the ... topic "cold fusion" being held here for the ... National Meeting of the American Chemical Society (ACS). "Years ...
... , , Michael M. Graham, Ph.D., M.D., president, ... chair, SNM Medical Isotope Task Force, Jeffrey P. Norenberg, ... member, SNM Medical Isotope Task Force, WHEN:,Immediately ... over a two-week period when cancer, heart and brain ...
Cached Biology News:Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products: